title: [New aspects in thyroid cancer treatment: Highlights of the ASCO Annual Meeting 2015].
abstract: At the beginning of June 2015, the Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in Chicago. A total of 24 studies in the field of thyroid oncology were presented, being discussed in the present review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. Kinase inhibitors are used primarily in the context of palliative treatment concepts. The most recent treatment options in thyroid oncology, both surgical and medical, are summarized in the following article.
authors: Univ.-Klinik für HNO Heilkunde, Kopf-Hals-Chirurgie und Onkologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Deutschland.
authors: B B
authors: BB
authors: Lörincz
authors: S
authors: S
authors: Topp
authors: R
authors: R
authors: Knecht
mesh_terms: D059248:Chemoradiotherapy / Q000379:methods*; D003131:Combined Modality Therapy / Q000379:methods; D019317:Evidence-Based Medicine; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D010166:Palliative Care / Q000379:methods*; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000628:therapy*; D013965:Thyroidectomy / Q000379:methods*; D016896:Treatment Outcome